Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that primary and secondary endpoints were not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its...
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed...